Coronavirus Update: Favipiravir Scores In Phase III Trial
Plus: UK Invests In 'At Risk' Vaccines Manufacturing.
Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.
You may also be interested in...
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Executives from Moderna, Pfizer and AstraZeneca and others will give politicians in Washington DC an update on the progress of their vaccine - but will resist pressure to make promises of a breakthrough in 2020.
The UK's vaccine strategy spread its bets over three candidates so far, as the country also looks to prove its world-class status in life sciences research and manufacturing.